Soon it may be T-A-N-E-Z-U-M-A-B!
Pfizers new biologic for treatment of pain associated with osteoarthritis. The new therapy just hit its endpoints in a phase III study with 690 patients who did not receive sufficient relief from NSAIDs or Cox-2 inhibitors.
Results are so good that Fierce Biotech reports that this drug is now the leading candidate to become the first mAb (and large molecule) to be approved for pain relief. This news has got the folks at Pfizer and its partner Xoma feeling no pain.
Posted by Bruce Lehr June 18th 2010.